secwatch.observer — SEC 8-K summary
======================================

Issuer:     Silo Pharma, Inc. (SILO)
CIK:        0001514183
Form:       8-K
Filed at:   2022-09-30T23:59:59+00:00
Accession:  0001213900-22-060406
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Silo Pharma closes $5.75M public offering at $5/share, uplists to Nasdaq; appoints new CFO and director
--------------------------------------------------------------------------------

- Closed underwritten offering of 1,150,000 shares (incl. full over-allotment) at $5.00/share, gross proceeds $5.75M, net ~$4.83M.
- Common stock began trading on Nasdaq Capital Market under ticker SILO on September 27, 2022.
- CFO Eric Weisblum resigned; remains CEO and President. Daniel Ryweck appointed CFO with $42,000 annual base salary.
- Board appointed Dr. Jeff Pavell as director and chair of nominating and corporate governance committee.
- Proceeds to fund product development, marketing, working capital, and potential acquisitions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1514183/000121390022060406/0001213900-22-060406-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1514183/000121390022060406/ea166467-8k_silopharma.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-060406

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer